Bayer Aktiengesellschaft (BAYN) Earnings Call Transcript & Summary

November 12, 2025

Deutsche Boerse Xetra DE Health Care Pharmaceuticals earnings 64 min

Earnings Call Speaker Segments

Jost Reinhard

executive
#1

Good afternoon, everyone, and good morning as well. Welcome to the call where we'll go over what we delivered in the third quarter of 2025. To get our presentation started today, Bill will lead off by covering how the business has performed so far this year along with a status report on where our strategic priorities stand. After that, Wolfgang will walk through the quarter's results in more detail, driver by driver, and then share our outlook. Once the prepared remarks wrap up, the two of them will be joined by the three presidents of our divisions to take your questions. Before we get going, please take note of the cautionary language contained in our Safe Harbor Statement. With that said, Bill, the floor is yours.

Bill Anderson

executive
#2

Thank you, Jost. And thank you, everyone, for being on the call with us today. We released our third-quarter results earlier, and as you could see, our sales came in slightly higher on a currency- and portfolio-adjusted basis, both for the quarter and for the year to date. As you'll notice, throughout today's presentation we cite sales growth figures that are adjusted for currency and portfolio effects. Core EPS stands at EUR 4.29, which is 7% above last year. Free cash flow came in at EUR -800 million, in line with what we had projected and with the seasonal pattern of our business. Here's how things look across our divisions. To start with Crop Science: Q3 is invariably a lighter quarter for our agriculture business, yet Crop Science kept demonstrating resilience. Sales are marginally lower nine months into the year, reflecting the substantial regulatory effects we are working through. Corn is ahead 9% this year, helped by solid Q3 growth from higher acreage in the U.S. and a strong beginning to the LATAM season. Our core crop protection business declined 2% in Q3 following the expiry of Movento's Europe license. Glyphosate, which we manage separately, delivered modest Q3 growth thanks to pricing. On the bottom line, we are capturing efficiency gains from our operating model and our profitability measures.

Bill Anderson

executive
#3

Although Q3 benefited from some favorable phasing, we are strongly positioned to meet our full-year commitments. Turning to Pharmaceuticals, the resilience of our top line continues to encourage us. Nubeqa and Kerendia both maintained their impressive momentum, with Nubeqa rising 60% year-over-year and Kerendia climbing almost 80% over that same period, driven in particular by robust growth in the U.S. and China. Eylea saw a decline in Q3. We faced considerable pricing pressure in Japan and Canada alike, along with certain one-time effects. We stay confident in our goal of keeping 2025 Eylea sales stable compared with 2024. Our year-to-date EBITDA margin stands at 26.1%. That is modestly below last year, reflecting pricing pressure, currency effects, and investments in our launches, yet we remain on track to finish inside the guidance we raised in summer. In Consumer Health, the market environment is increasingly challenging, especially in the U.S. and China. Against that backdrop, our year-to-date growth currently trails our full-year projection because of the soft market environment. We anticipate these dynamics will add further pressure on top-line growth in Q4, so we are reducing our 2025 sales growth expectation for Consumer Health. No matter how the market evolves, we are committed to an EBITDA margin in line with our 23%-24% guidance and to continued strong cash contributions.

Bill Anderson

executive
#4

So all in all, it's been a pivotal year, and we're well placed to hit the 2025 group guidance that we raised last quarter. There's still more work ahead this year and further out. As we look to 2026, we expect continued growth from Nubeqa and Kerendia, along with the first meaningful sales contributions from Beyonttra and Lynkuet, for which we just secured FDA approval. We stay confident that our dynamic shared ownership system will keep delivering efficiency gains consistent with what we've committed to. We recognize there are challenges to work through, among them declining Xarelto sales, currency headwinds, and a degree of trade uncertainty. That said, taking it all together, we have confidence in our improvement plan and in where our business is headed. We're in the process of finalizing our assumptions and will offer greater transparency on 2026 during our call on 2025 full-year results. That happens in February. Now let's turn to our strategic agenda. I'll highlight a few items shown on this slide. In our Pharma pipeline, we announced FDA approval of Lynkuet only two and a half weeks ago, and we anticipate it entering the U.S. market this month. In addition, our cell and gene therapy assets targeting Parkinson's are progressing well, and they are now in phase three and phase two, respectively.

Bill Anderson

executive
#5

Also, we’ve just announced study data for Kerendia in patients who have chronic kidney disease linked to type 1 diabetes, which makes it the first medicine in more than 30 years to show positive results in tackling the elevated risk of kidney disease progression and cardiovascular events among this patient population. On the litigation side, with each prong of our strategy moving forward, we can see more clearly the routes to meaningful containment. I use routes in the plural because there is more than a single way to reach that point, and any one route by itself will not suffice. We are achieving meaningful progress, and we feel confident about our goal of meaningfully containing the litigation risk by the end of 2026. This is where we currently stand. I’ll begin with PCBs. We recently got an adverse verdict in the PCB Erickson case from the Supreme Court in the state of Washington. That verdict confirms that our earlier choice to reach settlements on the remaining Sky Valley cases was the correct one. Even so, we disagree with that decision, and we agree with the dissenting justices who concluded that the court’s opinion was judicially inconsistent regarding the statute of repose issue. For that particular case, we are weighing further legal options.

Bill Anderson

executive
#6

Broadly speaking, we'll keep weighing every possibility to reduce the company's risk exposure. Regarding the glyphosate litigation, we anticipate a recommendation from the US Solicitor General on whether the US Supreme Court ought to take up our case. We stay optimistic that this recommendation will come through in time for the present session, which wraps up in June 2026. That's a significant decision, and we have plans ready for every scenario. On the legislative front, our view remains that U.S. farmers require certainty. That's especially so when farm economics are difficult. Federally, the Appropriations Bill and the Farm Bill both matter as legislation that strengthens clarity on the way essential crop protection tools get regulated within American agriculture. Congressional activity has been slowed by the government shutdown. Making progress is essential, and we're pressing that argument. On the state side, another cycle of legislative sessions starts soon, kicking off in January. We see it as very important to stand up for the work American farmers do, and we'll advocate for the innovation and the regulation they require. All in all, we recognize that a pivotal and very fast-moving period lies ahead of us.

Bill Anderson

executive
#7

This dynamic shows up in our provision, which shifted during the last quarter because of several factors. For instance, following Q2, we disclosed a number of confidential settlements, and after that came a moderate rise in glyphosate case filings. It makes sense that the possibility of settlements would drive the case count higher, and we anticipate that trend will persist as our containment efforts mature. More cases mean more provisions, and litigation costs add to them as well. At the same time, we have settled some of the verdicts during both the appeals stage and the post-trial motion stage, since resolving them was beneficial for capping the company's exposure. Lastly, the recent PCB Erickson verdict prompted us to adjust our provision upward. I mention this context because it illustrates what we anticipate in the phase ahead: significant decisions, some within our control and some beyond it, that carry major implications for how we move forward and for the future of glyphosate in American agriculture. We are confident that our multi-pronged strategy is the correct one. As we keep pushing it forward, we will keep refining how we approach resolution, assessing each option for future optionality, finality, cost, and risk. Turning to cash and deleveraging, net financial debt declined further in Q3, and we reaffirm our full-year free cash flow outlook, including litigation-related payouts.

Bill Anderson

executive
#8

Crop Science is putting intense emphasis on carrying out our five-year plan. We're busy simplifying both the portfolio and the operations — 12 active ingredients are being outsourced, and 150 products are being discontinued. That strategic concentration lets us zero in on innovative crop solutions. A great illustration is Plenexos, which we recently introduced. This advanced insecticide reached the Latin American market just last week. Last, regarding our operating model, we're seeing gains on both the top and bottom line. The organization keeps becoming leaner and more efficient, and we're realizing advantages in speed and focus. I'll finish with an example from our Pharmaceuticals division. Twenty months ago, we announced an agreement to in-license Beyonttra in Europe. Before that, many people within the company simply weren't aware of this medicine. By April of this year, we had brought it to market in Germany, and the first European patients could receive Beyonttra. As of today, the medicine has made a strong start and is already surpassing our ambitions for 2025. Just months into the launch, we've achieved roughly 50% market share in new-to-brand prescriptions in Germany — one of the fastest uptakes we've witnessed for a cardiovascular treatment. The teams are now concentrating on establishing Beyonttra as the new standard of care in its treatment setting.

Bill Anderson

executive
#9

They credit their speed and success partly to their capacity for eliminating inefficient handovers, to flexible allocation of resources across markets, and to a sharp focus on the most important work. With that said, I'll pass things to Wolfgang. Before I do, you saw the announcement last week of Wolfgang's successor. Judith Hartmann joins Bayer in March of next year, and she takes over as CFO on the 1st of June. Judith carries a wealth of finance and leadership experience spanning industries and countries, and we look forward to welcoming her. It's far too early to say goodbye to Wolfgang, who retires in June of next year, as previously communicated. A crucial period lies ahead for the company, and he will be dialed in on delivering 2025, planning 2026, and continuing our efforts to significantly contain litigation. Wolfgang, I look forward to continuing to work with you on that, and I'll hand it over to you.

Wolfgang Nickl

executive
#10

Thanks a lot, Bill, and hello from me as well. First, let's take a look at the group picture for Q3. Net sales were up 1% compared with the prior-year quarter on a currency- and portfolio-adjusted basis. On a reported basis, we posted a decline of 3%, as continued foreign exchange headwinds weighed on our top line to the tune of roughly EUR 450 million. In a seasonally low quarter, EBITDA before special items reached EUR 1.5 billion, which was 21% higher than the prior year. That increase came largely from improved Crop Science and reconciliation results, which offset a decline in Pharmaceuticals. Let me stop there for a moment and provide a bit more context on the reconciliation line. It contains a fairly predictable element for our enabling function costs that can't be clearly allocated to the divisions. On top of that, there are other elements — mainly incentive provisions, side businesses such as our soccer club, and balance sheet-related hyperinflation effects — that are less predictable. These factors can swing considerably from one quarter to the next and against the prior-year periods. In Q3, the main drivers versus last year were lower expenses for personnel-related adjustments and lower hyperinflation effects, while additions to long-term incentive provisions were on par with the prior year.

Wolfgang Nickl

executive
#11

Looking at the whole year, we expect favorable enabling function costs, plus some positive one-offs in our side businesses. Some pieces could still shift, but our current expectation is roughly EUR -400 million in recon, EBITDA before special items for 2025 — an improvement of around EUR 100 million compared with what we guided before. Core earnings per share came in at EUR 0.57, which is EUR 0.33 higher than the prior year quarter, mainly because of the higher EBITDA and a better core financial result. That core financial result was up by roughly EUR 56 million year-on-year, driven mostly by lower interest expenses thanks to lower debt. In the appendix to this presentation, we've included the bridge from core to reported earnings per share, which for the quarter came in at EUR -0.98. The main driver of that delta, besides the regular amortization of intangibles, is additional litigation-related provisions that are classified as special items, totaling EUR 934 million. These cover amounts for the glyphosate litigation, reflected in a higher case count, other litigation costs, and the settlement of some cases that it was strategically advantageous to resolve, as Bill also mentioned in his remarks. We've also adjusted the provision for the impacts of the PCB Erickson ruling the Washington Supreme Court recently handed down.

Wolfgang Nickl

executive
#12

Free cash flow for Q3 landed at roughly EUR 0.6 billion. The change from a year earlier stems primarily from larger settlement payouts. Net financial debt fell by around EUR 600 million to EUR 32.7 billion relative to the close of Q2, largely on the back of operational cash inflow. Versus the prior year, net financial debt was lower by roughly EUR 2.3 billion. Now let's dig into how each division performed. In Crop Science, third-quarter net sales reached EUR 3.9 billion, a rise of 1% from a year ago. Demand proved robust with volumes climbing, above all in Corn and crop protection, which more than offset regulatory hurdles and pricing pressure. Our core business posted 1% growth versus the prior year, and Seeds & Traits was up 7% in the quarter. Corn sales climbed 22%, largely on U.S. acreage expansion and a strong opening to the Latin America season, supported by acreage recovery and the performance of our products. Hybrid performance proved strong this year, showing solid resilience against the heavier southern rust pressure observed in the U.S., while uptake of new corn technology almost doubled year-over-year. Our Soy and Cotton businesses felt some end-of-season effects in North America stemming from the dicamba label vacature and a smaller planted acre area in the U.S., even as we recorded growth in Vegetable and other Seeds & Traits during the quarter.

Wolfgang Nickl

executive
#13

Core crop protection was down 2% in the quarter, with pricing pressure still a factor. Among the other drivers, Insecticides fell 9% because the Movento registration expired in the EU, and Fungicide sales were lower, partly offset by stronger demand for non-glyphosate herbicides. Glyphosate sales rose 1% versus the same quarter last year, since generic reference pricing has recovered above the 15-year historical median price, and we raised prices in the United States. That said, delayed purchases in Latin America shifted some volume into the next quarter. Turning to profitability, EBITDA before special items reached EUR 172 million, a margin of 4.5% in what is seasonally our weakest quarter. The margin benefited from favorable COGS as well as intense expense management. Let's now turn to how Pharma performed. Net sales matched the prior year, up 0.4% at EUR 4.3 billion. Our launch brands, Nubeqa and Kerendia, kept up their strong growth momentum, which more than offset the anticipated LOE-related declines in Xarelto. Nubeqa was up 56% against the prior year quarter, with strong growth continuing across regions. In the U.S., significant volume expansion more than offset the pricing pressure related to the IRA. Kerendia grew 85%, driven in particular by the U.S.

Wolfgang Nickl

executive
#14

And China. Combined, the two launch brands posted EUR 843 million in net sales for the third quarter and EUR 2.2 billion across the first nine months of this year. I'd hope you'd agree with me that this is an impressive figure, and we're well on track toward reaching consensus for full year 2025. Eylea kept delivering solid volume growth along with a rising contribution from the 8 mg dose, which made up 27% of total Eylea sales. That said, we also saw mounting pricing pressure, most notably in Japan and Canada. On top of that, sales took a negative hit from an order shift into the fourth quarter in Japan, plus a one-time reimbursement benefit in the U.K. from the prior year. Taken together, this produced an 11% sales drop in Q3 and a decline of -1% year to date. Even with this soft quarter, we stay confident in maintaining our full-year ambition of stable sales versus last year. As for Xarelto, generalization proceeded as expected, bringing about a 31% decline last quarter. Lastly, our base business held up robustly, with strong volume growth in radiology and an 11% increase in women's health, which largely offset VBP headwinds in China as well as declines in hematology.

Wolfgang Nickl

executive
#15

For the bottom line, EBITDA before special items declined 5%, landing at roughly EUR 1 billion, with a margin of 24.1%. That lower margin compared with the prior year came primarily from reduced pricing and increased growth investments, and those factors were nearly offset by greater volumes, smaller year-on-year incentive true-ups, and ongoing savings from our efficiency programs. Sales in Consumer Health rose 2% during Q3, with price and volume each contributing in a balanced way. Absolute sales were flat year-over-year, since portfolio gains from the Natsana business offset substantial foreign exchange headwinds. Strong category growth in Dermatology, Digestive Health, and Pain & Cardio was driven by our focus on innovation, power couples, and more agile resource allocation. Broadly, we expect challenging market conditions, particularly in the U.S. and China, including weaker consumer sentiment and store closures. Against that backdrop, allergy and cold fell 8%, cycling over a strong prior year quarter. Seasonal preorders for cough and cold products were fulfilled in Q3 because of lower incident levels than in previous years and continued scrutiny from retailers to carefully manage inventory levels. We anticipate softer orders in Q4. Nutritionals grew by 1%, with gains in EMEA and LATAM, while consumption in the U.S.

Wolfgang Nickl

executive
#16

China is still down because of consumer confidence. Our EBITDA margin before special items came in at 25.7%, which is EUR 363 million in absolute terms, and both figures are in line with last year. That shows the strengths of our new operating model and disciplined cost management, while we keep investing sufficiently in our innovative brands to foster consumption and to reach more people with self-care products. Year to date, our margin stands at 23.9%, in line with our guidance range. Given the year-to-date performance, we feel confident in the full-year outlook for Crop Science and Pharmaceuticals, both on the top and bottom line. For the fourth quarter, we expect the following developments. In Crop Science, growth in the fourth quarter is driven by glyphosate, which is now anticipated at the upper end of our full-year sales guidance range, but will have a dilutive impact on margin in Q4. In addition, growth is anticipated for Latin America, recovering from a weak prior year period. For our Pharma business, we anticipate increased pricing pressure for Eylea in conjunction with the entry of 2 mg biosimilars in Q4. In addition, we expect continued generalization of Xarelto, as well as volume-based pricing procurement-related impacts on our business in China.

Wolfgang Nickl

executive
#17

We anticipate that the ongoing expansion of our launch assets will offset these headwinds. Regarding our margin, we expect accelerated launch investments in Q4—for instance, tied to our liquid launch activities. For Consumer Health, we already highlighted the lower end of our sales growth guidance range for the full year during our Q2 call in August. Given our significant exposure to markets with challenging dynamics like the U.S. and China, we now expect full-year sales growth for Consumer Health to land in the range of -1% to +1%. This does not impact our group outlook. Working closely with retailers, we will carefully manage the balance of sell-in and sell-out to ensure sustainable growth going forward. On profitability, we are committed to achieving the expected EBITDA before special items margin range of 23%-24% for the full year. Based on month-end September rates, we see similar foreign exchange effects for all three divisions compared to prior guidance. Let's wrap up with the group outlook for 2025 and early insights into the business drivers for 2026. Overall, for the group, we confirm our full-year 2025 outlook at constant currencies and the latest currency estimates, which did not change materially from month-end June rates when we compare it to month-end September rates.

Wolfgang Nickl

executive
#18

Simultaneously, we are revising the assumptions used in our modeling for special items, reflecting the extra provisions tied to litigation that were recorded during this quarter. Our current expectation for special items across the entire year is a range of EUR -3.5 billion to EUR -4 billion. As I noted earlier in my remarks, we likewise modified the recon modeling assumption. Now let's take a very quick look at 2026. Within Pharma, we will keep ramping up Nubeqa and Kerendia, scale Beyonttra, and bring Lynkuet to market. Regarding Xarelto, we anticipate declines at a percentage range comparable to what we saw this year. With Eylea, we will obtain additional insight into how market dynamics are evolving, aiming to generate volume growth for the 8 mg dosage. Turning to Crop Science, the agricultural market outlook remains quite dynamic. We are watching acreage development, especially given geopolitical uncertainty. In Corn, our plan is to generate growth through our refreshed portfolio while building on sustained technology adoption. For Soy and Cotton, we are relying on the dicamba registration for the upcoming season. On the whole, we stay sharply focused and remain on track to fulfill our five-year framework. In Consumer Health, although we faced certain challenges in key markets during this year, the broader market growth trends appear intact.

Wolfgang Nickl

executive
#19

We'll keep putting money behind our brands so we can meet what consumers need and boost consumption by growing household penetration. When it comes to geopolitics, we've gotten a bit more clarity over the past few weeks regarding EU-U.S. pharma tariffs. Some individual companies have announced truck pricing deals, but certain questions stay unresolved — especially those concerning sectoral pharma tariffs or possible policy changes in other nations. Meanwhile, our cross-functional teams demonstrated their strengths in handling the situation and curbing potential impacts for this year. Going forward, we'll keep watching developments carefully, and we will build the most likely scenario into our planning for next quarter. We're also tracking U.S.-China trade relations very closely. Since we're innovating for the good of our patients, farmers, and consumers across all markets, both the U.S. and China remain mission-critical to us. Turning to foreign currencies, this is a major headwind swing factor for the business, and as noted before, we anticipate significant currency headwinds persisting in 2026. To wrap up, we are fully focused on effectively managing what's within our control, adapting quickly to new realities, and moving forward with our transformation. We're currently finalizing the picture for 2026, and we will share specific guidance alongside our full-year 2025 results at the end of February.

Wolfgang Nickl

executive
#20

With that, Jost, please take over and facilitate the Q&A.

Jost Reinhard

executive
#21

Thanks, Wolfgang, and thanks, Bill. At this point we'll move into the Q&A, and Bill and Wolfgang are being joined by the three presidents of our divisions. A few housekeeping notes before we begin. Should you have a question, kindly raise your hand and then follow the directions given in the chat. To let as many participants as possible take part, as always, please keep to two questions. Today's first question is from Thibaut Boutherin at Morgan Stanley, and after him comes Sachin Jain of Bank of America. Thibaut, go ahead.

Thibault Boutherin

analyst
#22

Thanks so much. First off, on Eylea and the 8 mg share: it came in at 27% for the quarter. My understanding was the goal had been to get to 50% by the end of the year. Penetration seems to be decelerating somewhat. Could you discuss the hurdles a bit and how that shapes your view on what erosion will look like next year? And maybe a quick one on Consumer. It's been a hard year for Bayer, as it has for everybody else, with the same headwinds hitting across the board. Regarding your 2026 remarks, you mention an unchanged growth trend. Should we read that as 2025 continuing, or as an expectation of a return to a more normalized trend, and how much visibility do you have into Consumer next year? Thank you.

Bill Anderson

executive
#23

Thanks. Stefan, would you like to say something about how Eylea performed?

Stefan Oelrich

executive
#24

Okay. Hello, Thibaut. Appreciate the question. Clearly, everyone here feels pretty good about the way 8 mg is doing. If you place that within the broader market picture, my expectation is that Eylea 8 mg will very shortly — in the quarter now beginning — move into the number two spot in ophthalmology, behind the 2 mg. The underlying dynamics remain unchanged. We continue to push toward that 50%. Getting there will be difficult if it proves achievable at all. As for the broader dynamics and what next year holds, naturally we will provide greater precision on guidance when we move into next year. One variable that, I have to say, is hard to pin down is what will unfold on the pricing side everywhere, since that sits somewhat beyond what we control. We are watching the markets and developments there. Broadly, looking at the third quarter, a few anomalies showed up. Wolfgang flagged some of them, since they stemmed from events particular to that quarter that ought not recur in the fourth quarter. An order in Japan was shifted. There was a situation in the U.K., along with some remaining items, Canada generics, and we will see additional generics arrive next year.

Stefan Oelrich

executive
#25

Please hold on. We're learning about some of these pricing changes as they happen. We're doing our best to stick with our aim of holding this steady for as long as possible.

Heiko Schipper

executive
#26

I'll take the Consumer Health question. Thibaut, thanks very much for asking. And thanks as well for recognizing the difficulties we're facing in 2025. As you said, these difficulties are being felt throughout the whole industry. If you look at our competitors, they're facing the same problems too. What we're seeing in 2025 is a major deceleration in two of our most important markets — market number one and two, the U.S. and China. Our current forecasts for the remainder of the year are that the U.S. will come in at roughly -1% growth, and China will be roughly flat. I'm referring to the markets. So how does that translate into how we perform within the market? One thing we keep examining is our sell-out. What I can say is that when we review that data, we're growing faster than our competitors. We're gaining market share, even with the market being quite soft. On your question about 2026, our current read is that although the markets will recover, particularly the U.S.

Heiko Schipper

executive
#27

And China isn't going to see a significant recovery. At the moment, we're expecting low single-digit growth in both markets — more like 1% for each of them, let's say. For the market as a whole, we're thinking somewhere in the 3%-5% range for the entire world. We'll keep growing in both markets. We have a lot of confidence in how strong our brands are, and we're seeing that in the market share growth. Yeah, we'll keep you posted. Much of this depends on how the two markets, the U.S. and China, recover.

Jost Reinhard

executive
#28

Thanks. One quick housekeeping note: there's a number in the queue we can't identify, and it starts with 1437. If that's you, please let the IR team know who you are so we can get you into the question line. Up next we have Sachin Jain from Bank of America, and after him, Richard Vosser from JPMorgan. Sachin, go ahead.

Sachin Jain

analyst
#29

Thank you, Jost, and thanks for taking my question. I have two. The first is on the financial side, I suppose, Wolfgang, and maybe Rodrigo should weigh in as well. I appreciate the high-level remarks about 2026. Obviously we're all waiting for a detailed guide in February, and I'm not requesting a guide, but at this same point last year you moved the year forward by calling out 2025. Since you haven't done that this time around, my assumption is that you're broadly at ease with where consensus sits, recognizing there are multiple moving parts. A related question, I guess: obviously you've listed quite a few pushes and pulls. I'm just wondering, when you think about the group, which division carries the greatest uncertainty for you? From your comments, it sounds like crops. Could you flesh out the pushes and pulls on crop growth for next year? And just a very quick one for Stefan. Nubeqa posted a big increase in sequential growth this quarter. Do you expect that trend to carry on? Anything specific worth calling out there? Thank you.

Wolfgang Nickl

executive
#30

Sure, Satchin, I can take that question. Yeah, our practice has always been to give guidance during the first quarter of the year for a particular year. We did see a bit of a disconnect last year between consensus and how the business was actually developing. That's likely why it seemed to you like we had provided somewhat more guidance. One of the subjects was indeed dicamba and what it would mean for the following year. This year, our aim was really more to lay out the different vectors at work across the three businesses and where we see tailwinds, where we see headwinds. Again, we'll give you more guidance as we move into next year. I flagged the FX piece because, in the current geopolitical environment, FX environment, that's obviously one of the things we can't predict so well. Yeah, it's sometimes hard to say, but generally speaking, a consumer business is more stable than a Crop business, particularly when you get the dicamba approval in again. Of course, we have to see how quickly the assets ramp in Pharma. We're very confident on that. Everything that's on our cost base, everything that's in our hand, we're pretty well on track to deliver.

Wolfgang Nickl

executive
#31

Take DSO, for example—we mentioned EUR 2 billion. We completed EUR 500 million and EUR 800 million, and next year we'll complete another EUR 700 million. Those are items within our control that we deliver on. We need to watch a bit more how acreage trends in Crop. We need to watch a bit more what unfolds on the macro front, and likewise a bit more in Pharma. I believe we have a pretty solid grasp of the tariffs, of what's going on with MFN. That's essentially repeating what we stated before. Bear with us, Satchin. There's more to come.

Bill Anderson

executive
#32

Rodrigo, perhaps you could give us a brief overview of what you view as some of the key dynamics heading into next year.

Rodrigo Santos

executive
#33

Sure, there isn't much I can add beyond what Wolfgang expressed so well, Satchin. One thing we're monitoring quite closely, I'd say, is how acreage is shifting, correct? Naturally, the tariffs and the current geopolitical climate are affecting U.S. Soybean. What kind of transition will we see next year? That's a factor we'll be keeping a close eye on. I'd say you've got the picture, right? We're aligned with this year's plans. That matters a great deal. This is what we told you on May 13 when we were together. Delivering 2025 was important. Naturally, 2026 is the first — another significant year, our five-year framework — and we're on track with that plan too. We'll have more to share next quarter, but some uncertainty around geopolitics and tariffs is influencing acreage. That's the item I'd point to here as well. Stefan, for the shout-out.

Stefan Oelrich

executive
#34

Yes, thanks. No, that's Nubeqa. Satchin, I appreciate you picking up on what a truly strong quarter Nubeqa is delivering. Trust me, I'm just as happy about it as you are — perhaps a bit less taken aback, though. The sequential growth is robust, exactly as we had anticipated. I don't want to give too much guidance, but I believe you'll keep seeing solid quarters ahead from Xarelto. Performance is very strong right across the board, especially in the United States and Europe, with volumes rising sharply. It's genuinely becoming the global standard of care for this indication. As new patients start and then stay on our therapy for a while, I think we're truly changing patients' lives, and that shows up in markedly better results. We couldn't be more pleased with this.

Bill Anderson

executive
#35

Satchin, I believe you've likely worked out that Stefan was referring to Nubeqa.

Stefan Oelrich

executive
#36

Was there something different I said?

Bill Anderson

executive
#37

You brought up Xarelto again there.

Stefan Oelrich

executive
#38

Oh, shoot.

Bill Anderson

executive
#39

I believe folks got the picture. Xarelto is in fact heading the opposite way, though Nubeqa is performing amazingly.

Jost Reinhard

executive
#40

Appreciate the clarification, Bill. Richard is now connected with us, and Laurent Favre of BNP Paribas comes after him. Richard, the floor is yours next.

Richard Vosser

analyst
#41

Thanks a lot, Jost. I've got two questions. The first follows up on what Satchin asked regarding Crop. Thinking through the dynamics for Soy and Corn next year along with pricing — perhaps you could give a bit more color on pricing. We'd probably expect there could be a shift toward Soy, though that's hard to predict, and maybe dicamba re-registration plays into that as well. When do you actually need that re-registration to be secured so you can recover next year? There are a few pieces there. Then just one on the Pharma business. Kerendia also showed an uptick, I believe, sequentially during the quarter, with some of the growth improving and accelerating here. Stefan, maybe you could speak to some of the drivers behind that — perhaps heart failure indications coming through and the runway we should expect here, and whether that acceleration is here to stay. Thank you.

Bill Anderson

executive
#42

Rodrigo, would you like to kick things off?

Rodrigo Santos

executive
#43

Thank you, Richard. To start, we feel good about the dicamba label for the upcoming season. The EPA has told us this is still a top priority for them—even with the U.S. government shutdown, it stays a key priority for EPA—and we're confident we will secure it in time for farmers next year. That will have a favorable effect on the first part of your question, the pricing of Soybean for us, correct? We are relying on that for next season, working on it of course, and we will have greater clarity when we get to the next quarter to share more details. We intend to obtain the registration for the season. It will be ready in time for that, and we will be able to achieve some price impact from it for our Soybean franchise and also our Cotton franchise, of course, as we have. That is part of the plan.

Bill Anderson

executive
#44

Stefan?

Stefan Oelrich

executive
#45

Hi, Richard. I appreciate the question on Kerendia — and perhaps I should be the one giving you the flowers. Your report was the first to highlight the superior potential of Kerendia, and I believe that is materializing now as we move forward. Yes, I think you can expect this positive trend to persist. I have consistently maintained that tremendous potential sat behind Kerendia, though it was a slow start. As with many analogs in cardiovascular, we've supported that start with additional data, and more data is still coming. I think we're seeing solid performance in kidney, and we're also seeing the first effects of the heart failure indication. Perhaps anecdotally from field visits, when I talk with my reps in the U.S., we're seeing very good reception of Kerendia in heart failure. The fact that it's synergistic with other therapies like SGLT-2, I think, adds to the very strong position that we now have across a variety of specialties for protecting both kidney, but also the heart. This is, I think, a sweet spot for us, and you can see, you will see continued growth. We'll discuss this in February in more detail.

Jost Reinhard

executive
#46

Thanks. Following Laurent Favre, Charles Pitman-King of Barclays will be up. Laurent, you’re next — go ahead, please.

Laurent Favre

analyst
#47

Thank you, Jost, and good afternoon to everyone. Bill, my first question concerns DSO. I believe we are still witnessing headcount decline of over 1%, in fact sequentially, and that has happened each quarter for two years now. I realize you never set a target for reducing headcount, but could you perhaps discuss, I suppose, how you view fixed costs evolving from this point? I suppose you have done considerable work in that area, but it appears that, I suppose, there is no letup. That is my first question. My second concerns PCB. Given that you have now had the unfavorable result in the Erickson appeal, is indemnification becoming the most critical element in containing PCB litigation, or do you have another lever available?

Bill Anderson

executive
#48

Okay, thanks, Laurent. On the topic of reducing headcount and rolling out DSO — I'd describe the past 18 months as the major surgery, because we understood that to bring in something like DSO, we first had to remove a lot of layers. Most areas of the company used to run somewhere between 11 and 12 layers. Today we're at six to seven layers. Essentially, five layers have come out across the board. We had roughly 15,000 managers, and today that figure sits at around 5,000 managers. That works out to a 2/3 reduction in people who manage other folks. We held on to the great majority of the talent needed to drive our progress, but we removed the gatekeepers who, frankly, at every large multinational, simply slow everything down and stop us from responding immediately to customer needs or pushing innovations forward. We now have weekly examples coming through of products launching in record time. Over the weekend I was in Brazil, and just as one example, roughly a year ago we had noticed influencers online.

Bill Anderson

executive
#49

They were using Bepanthen and combining it with Rose Hips so they'd get an added benefit. Bepanthen is a skincare product that accomplishes several things. Anyway, we spotted this, and our team asked, "Hey, why is somebody else out there selling this?" Once they received the list of roughly the 10 reasons we couldn't proceed quickly, they realized, "No, actually, we can." That product went to market roughly nine months after the first sign of market interest. We came out with a Bepanthen Rose Hip version, and that has contributed 20% to our Bepanthen sales this year. Bepanthen is our largest product in Brazil. This illustrates things that — we see examples similar to this at least weekly — of things that previously would have required two years or three years or would never have happened, and now they come together in weeks or months. We are genuinely excited about how that is progressing. When it comes to headcount reduction, we performed the major surgery to put ourselves in the right place. Going forward, we think we still have plenty of opportunities to move faster and to make the system work for us.

Bill Anderson

executive
#50

You'll likely see total headcount keep coming down somewhat, though I'd expect that to be less major surgery and more incremental attrition, that kind of thing. Beyond that, of course, there's the five-year frame we have in Crop Science for improving overall profitability in Crop Science. That's another area where some headcount reduction will happen. I think you should expect it to keep going down, but not at the same rate it has over the last 18 months.

Wolfgang Nickl

executive
#51

Should I go ahead with that?

Bill Anderson

executive
#52

Sure, go ahead.

Wolfgang Nickl

executive
#53

Laurent, on the PCB matter I can likely offer a couple or three sentences. Bill covered it in his remarks: "No, we didn't like the outcome on Erickson, but we were pretty satisfied that we could solve quite a bit of ongoing procedures and on all four future procedures in Washington State." Beyond that, many specifics surround it. There is, for example, a case management order from the court that makes filing future cases there harder. Your question was about the indemnification process. I can't go into every detail on that, but you should rest assured that we pursue aggressively the parties to whom Monsanto or its predecessors sold the PCB, and there is more to come on that front. It has not been forgotten. By the way, that applies not only to Erickson. It applies to all the past cases and potential future resolutions, including in states as well. I hope you can bear with me. I can't provide much more detail beyond that, but rest assured we are going after it.

Jost Reinhard

executive
#54

Good. Joining us now on the line is Charles Pitman-King of Barclays, and Christian Faitz from Kepler Cheuvreux comes after him. Charles, the floor is yours.

Charles Pitman-King

analyst
#55

<<inaudible>> King at Barclays here, with a couple of questions, if I may. First, on Beyonttra — with the strong launch and the recent PDUFA for elinzanetant, how do you view what these launch assets will contribute as we look toward 2026 and beyond? Noting that Beyonttra got to market with high speed, I'm curious what initial KOL feedback you're hearing on the launch, and what you expect in terms of an accelerated launch for elinzanetant, given less onerous monitoring requirements versus competitors. Second, on the Crop business, thinking about U.S. and China policy risks or possible tailwinds, could you touch on or give us further insight into what the potential impact for Bayer could be if China, for instance, did not purchase from the U.S. in as high detail and in high quantities as it has historically, and what you're predicting there. Thank you.

Bill Anderson

executive
#56

Alright, Stefan, over to you.

Stefan Oelrich

executive
#57

Thanks, Charles. Yes, we're happy — very happy — with how Beyonttra has been taken up. Bill mentioned a 50%+ new-to-brand RX figure in Germany, and you heard that. Obviously, I think that stands as evidence of what most of the KOLs are also telling us, since this is a product that isn't widely prescribed by a large number of physicians. Typically in Germany, patients get referred to teaching hospitals and university centers, and that's where the product is then prescribed, given that it's a high-priced cardiology product. The feedback we're receiving has been overwhelmingly positive. Beyonttra is really viewed as a near-complete stabilizer of TTR, and I think that genuinely sets up a strong differentiation against other products on the market. We also need to acknowledge that although this is a very strong and fast ramp-up when it comes to new to brand — which is extremely positive and exciting — we aren't necessarily seeing the same hold true for switches from existing therapies. There, the marketplace is a little bit more stable. Getting through the entire market is going to take time. Depending on the market, we're also seeing extremely strong uptake in other markets where we've launched, such as Denmark, for example.

Stefan Oelrich

executive
#58

All right, thus far things look encouraging regarding what this implies for Lynkuet and Beyonttra going into next year. On Beyonttra, I think it's fair to assume we'll pick up somewhat more in new-to-brand, yet I believe it plainly shows we can aim at becoming a category market leader across Europe. As for Lynkuet, we'll need to watch how things unfold a bit. We're feeling quite bullish, given our track record in women's health. Beyond that, I believe that offering women a new choice for treating menopausal symptoms — the timing really couldn't be better for a launch in this space. The media reaction to our approval has been rather surprising, something we hadn't seen in a very, very long time, and that demonstrates just how much this is genuinely a topic of today. We're getting ready. The first Lynkuet sales in the United States were actually recorded this week, and we're preparing to look at sequencing this into the rest of the world. Stay tuned. I think we can truly make a difference. Our label is differentiated versus anything available out there. We have the experience. In women's health, people know who Bayer is, with 100 years of history.

Stefan Oelrich

executive
#59

There's potential for this to be a strong one, though we're only at the beginning. Let's get the work done first, and after that we can also celebrate a bit, the way we've done with a few of these other launches. I don't need to tell you that I'm extremely excited about every one of our launches, and they truly are meeting the blockbuster potential I had told you about. Keep watching for more in February.

Rodrigo Santos

executive
#60

That's really cool to hear, Stefan. Let me speak to the question about market dynamics here. In a normal situation, we had a very — this past season, we had a very large corn area in the U.S., 98 million acres. With a normal crop rotation, next year you would come to probably close to the historical level that you see in the U.S., around 91 to 92 million acres. That would be under normal circumstances. As you mentioned, the trade-off would be that you'd see a significant increase in Soybean area. There's a lot of uncertainty right now tied to the agreements between China and the U.S. If that agreement is put in place, that's probably exactly what you'll see in the market. If not, as you said, you could see a larger Corn area and more Soybean coming out of Latin America. What I feel strongly about in our case is that our position in both Corn and Soy in North America and in Latin America puts us in a good spot to be ready for that market. Hopefully, by next quarter, we'll be able to gain more insight into how this trading will conclude, and then we'll be able to be more precise for next year's guidance.

Rodrigo Santos

executive
#61

Keep watching for more on that. Come February, we will definitely be discussing it. Thanks.

Jost Reinhard

executive
#62

That's great.

Charles Pitman-King

analyst
#63

Much appreciated.

Jost Reinhard

executive
#64

Next up in the queue is Christian Faitz of Kepler Cheuvreux, and after him comes Joel Jackson from BMO. Our final questioner today will be Florent Cespedes of Bernstein. Christian, the floor is yours.

Christian Faitz

analyst
#65

Yeah, thanks, Jost, and hi everybody. Good afternoon. I’ve got two questions, please. First, on the short stature corn ramp-up, where do things stand when it comes to sales dynamics there? And my second question is, could you give us an update on how Bayer’s effort is going to get a major glyphosate case before the US Supreme Court? Thanks a lot.

Bill Anderson

executive
#66

Rodrigo, would you like to kick things off with Preceon?

Rodrigo Santos

executive
#67

Absolutely. I'm really pumped to discuss that. Over the past few months, I was out in Iowa, strolling through a field alongside a farmer who was pulling in 300 bushels per acre with the new launches. It's genuinely awesome to witness what's happening in the market. This year, we're expanding to 600 farmers, who had 80,000 acres in the U.S. That's the groundbreakers effort we're carrying out with the breeding version. Next year, we'll scale to 200,000 acres in the U.S. as we get ready for the big breakthrough — the biotech launch we have planned for 2027 and beyond. There's a lot of enthusiasm across the organization about the Preceon launch in the coming years. We're collaborating very diligently with every farmer in the groundbreaker exercise to ensure they capture the maximum value from the technology. Once again, delivering higher yields, greater stability, a wider experience while giving them more flexibility in how they manage the field is truly exciting to watch. Next year will mark another step toward that and toward really preparing the launch of the biotech version that will let us reach truly broad acres in the U.S. Also, I should mention that we currently have this happening in Europe too — a lot of excitement around silage with farmers as well when you visit Italy and some other places.

Rodrigo Santos

executive
#68

We're also growing to nearly 100,000 acres over in Europe with the short stature corn sets. There's great momentum, and we're getting ready for the full launch of the biotech version in the U.S.

Bill Anderson

executive
#69

Yeah. Thank you. Thank you, Rodrigo. I was over in Greece not long ago, and I also heard stories from a key partner of ours in Southern Europe regarding short stature corn and the difference it makes. What I mean is, dairy farmers are telling us, "Hey, yeah, basically the cows give more milk on short stature corn." Some agronomists in academia have now documented this—essentially the corn contains less lignin, which makes it easier for dairy cattle to digest, and they like it. That's one more bonus that comes from innovation. On the question about the Supreme Court petition—that's the Durnell case on glyphosate, that appeal—we stay optimistic that the US Solicitor General will give a recommendation to the Supreme Court on this case in time for the Supreme Court to hear it during the current session, which finishes in June of 2026. We're hopeful that will occur within the next couple of months or so. Let me just remind you that we see it as an important chance for the court to clarify the authority of the EPA when it comes to pesticide labeling. It isn't our only approach, and that's the reason we have this multi-pronged approach.

Bill Anderson

executive
#70

Hopefully we’ll get our opportunity before the Supreme Court, and that’s something we’re looking forward to—but there are other efforts we’re pursuing at the same time, and those would factor into wrapping things up. We also have additional avenues, and our plan is to use every tool available to us so we can keep pushing until this is finished.

Christian Faitz

analyst
#71

Thank you so much, to both of you.

Jost Reinhard

executive
#72

Alright. We’ll finish up today with questions from Joel Jackson at BMO and Florent Cespedes at Bernstein. Joel, you’re up next.

Evan Seigerman

analyst
#73

Hello again, and good afternoon. This is Evan speaking on behalf of Joel. I'd like to ask about how concerned you are regarding the increasing generic competition in crop protection — both for glyphosate and for the non-glyphosate parts of the business — and how that shift affects the way you view the crop protection opportunity ahead. Thank you.

Bill Anderson

executive
#74

Alright, Rodrigo, the floor is yours.

Rodrigo Santos

executive
#75

Thanks, Joel. It ties in closely with what we discussed on May 13, doesn't it? If you look more closely at the presentation we gave on May 13, our perspective on crop protection comes down to these three elements for how we need to handle it. That's the market reality, and these are the three elements for managing it. One is innovation, and you've just heard some examples of that, right? Plenexos, we just recorded the first sales, as Bill mentioned, in Latin America. We're going to take this to 70 countries, 50 crops. We are submitting just now to the key markets, Icafolin. We have Convintro, a new herbicide awaiting regulatory approval in the U.S. We have Verango Prime in Latin America and in Brazil set for a very good expansion as well, along with Fox Xpro and Curbix. Innovation is certainly one element. The second element is all the effort we are making to be competitive. You heard from AI Bay AI, which are the ones we're going to produce in Germany, which are the ones we are outsourcing, the divestment of some of the low-margin products and some of the phase-out that we had.

Rodrigo Santos

executive
#76

So this is the crop protection portfolio's life cycle, and it matters a great deal. Last, I'd note that we've spent the past two or three years on this, and you've heard me touch on operational excellence in the field before. We're shifting our crop protection work heavily toward — can you hear me? Yeah, I think so. We're moving in this direction to ensure that our whole focus — the entire team's esteem — went to sell-out rather than pushing our incentives or our partners' incentives. That gets a very high priority: keeping channel inventory at the lowest possible level. Given the new dynamics we see in crop protection, you'll need innovation, but you'll also need to be cost-competitive and highly effective in operations. That, we believe, is the new plan, and it lines up very closely with the five-year framework we laid out. Thanks for the question.

Jost Reinhard

executive
#77

Thanks, Evan, and apologies for mixing up the names. With that, we'll wrap up today's session with Florent Cespedes of Bernstein.

Florent Cespedes

analyst
#78

Good afternoon, and thanks for taking my questions. I have two quick ones, please. First, for Stefan on Pharma: could you maybe give us a bit more color on the business dynamics in China and how you see the trend shaping up for 2026? My second question is on Consumer: what could re-energize that business in the U.S. and the rest of the world? Are there any subdivisions that might be a little bit stronger next year? Some color on this front would be helpful. Thank you.

Bill Anderson

executive
#79

Over to you, Stefan.

Stefan Oelrich

executive
#80

Hello, Florent. Yes, China. Overall, we're actually having a pretty solid year there, even with the VBP pressures affecting cardioaspirin and some smaller brands. That will wash out over the course of next year. Past that, we're seeing a genuinely healthy trend. At this point we've essentially gotten through everything related to VBP, and we'll be clean for the years ahead. China looks good going forward. I can't say more than that right now.

Florent Cespedes

analyst
#81

All right, thanks.

Heiko Schipper

executive
#82

Right, Florent, and I’ll handle the questions on Consumer Health. Although we’re concentrating heavily on the U.S. and China, and you’ve heard all of us discuss the downturn and the weakening in those two markets, what actually gives us a great deal of optimism is that other markets are performing really strongly. We don’t mention that often enough. Take region Europe, for instance: while you’re seeing some consumer sentiment there also picking up on what’s happening in the U.S. and China, it isn’t to that degree. We’re actually doing very well. We track the evolution index constantly. In Europe, we’re above 100. That means we’re gaining market share. In China, although the market is down, we have EVIs of about 105. Very, very strong business performance. The same is true in Latin America and the rest of Asia-Pacific. What gives us confidence that the business will keep growing is basically just the strength of our brands and the people behind our businesses in every single country. We are very confident about that and about how we are bringing the products into the market.

Heiko Schipper

executive
#83

To reiterate what I said, the fundamentals of this market remain extremely, extremely robust and very solid. As I noted before in response to Thibaut, our view is that this market will land somewhere in the 3%-5% range. Although growth in the U.S. and China won't be particularly strong, the remaining regions will make up for it. Our position in every one of those regions is going to accomplish that. Along with that, the market itself, innovation, how strong our brands are, and the strength of the people supporting them mean we'll keep being a highly successful Consumer Health business.

Florent Cespedes

analyst
#84

Alright. Thanks a lot for clearing that up. Appreciate it.

Jost Reinhard

executive
#85

That’s great. I really appreciate your questions and your interest today. And thanks for the answers. So with that, we’ll bring our Q3 earnings call to a close, and I hope you all have a very good day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Bayer Aktiengesellschaft transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Bayer Aktiengesellschaft earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Bayer Aktiengesellschaft or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.